CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Regeneron reports 84-week Phase III data for Pasatru in adult FOP

Phase 3PasatruNeutral
AI Analysis

Summary

Regeneron reported 84-week Phase III data for Pasatru in adult FOP. No details on efficacy outcomes, patient numbers, or primary endpoints were provided in the article.

Clinical Trial Data

Phase

Phase III

Importance:6/10
Sentiment:
0.00
Phase 3Data ReadoutPasatruFOPClinical Trial
Related Companies

Read the original article

Published by yahoo_finance on October 13, 2026 11:00 AM

Read Original